U.S. markets closed
  • S&P 500

    4,432.99
    -40.76 (-0.91%)
     
  • Dow 30

    34,584.88
    -166.42 (-0.48%)
     
  • Nasdaq

    15,043.97
    -137.93 (-0.91%)
     
  • Russell 2000

    2,236.87
    +3.96 (+0.18%)
     
  • Crude Oil

    71.96
    -0.01 (-0.01%)
     
  • Gold

    1,753.90
    +2.50 (+0.14%)
     
  • Silver

    22.42
    +0.13 (+0.58%)
     
  • EUR/USD

    1.1733
    -0.0039 (-0.3285%)
     
  • 10-Yr Bond

    1.3700
    +0.0390 (+2.93%)
     
  • Vix

    20.81
    +2.12 (+11.34%)
     
  • GBP/USD

    1.3739
    -0.0058 (-0.4177%)
     
  • USD/JPY

    109.9390
    +0.2210 (+0.2014%)
     
  • BTC-USD

    47,476.61
    -451.93 (-0.94%)
     
  • CMC Crypto 200

    1,193.48
    -32.05 (-2.61%)
     
  • FTSE 100

    6,963.64
    -63.84 (-0.91%)
     
  • Nikkei 225

    30,500.05
    +176.75 (+0.58%)
     

Here's Why Cytosorbents Is Up 17% Today

·2 min read
Here's Why Cytosorbents Is Up 17% Today
In this article:
  • Oops!
    Something went wrong.
    Please try again later.

Shares of Cytosorbents Corporation (NASDAQ: CTSO) jumped 17.3% on Tuesday, spurred higher by news that the Investigational Device Exemption (IDE) request for its DrugSorb-ATR Antithrombotic Removal system has been approved by the U.S. Food and Drug Administration, allowing clinical trials of the device to move forward. Cytosorbents' DrugSorb-ATR Antithrombotic Removal device just cleared another regulatory hurdle. Exempt from certain other steps that some medical devices must go through, the company can now begin testing the device, which allows patients undergoing heart bypass surgeries to curb the amount of blood-thinning drug ticagrelor in the bloodstream during and after the procedure.